Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 12/5/2016 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Thomas Aasen?

Thomas H. Aasen

Executive Vice President, Chief Financial Officer and Chief Business Officer

ACADIA Pharmaceuticals Inc.

HQ Phone:  (858) 558-2871

Direct Phone: (858) ***-****direct phone

Email: t***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

ACADIA Pharmaceuticals Inc.

3611 Valley Centre Drive Suite 300

San Diego, California,92130

United States

Company Description

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has a pipeline of product candidates led by NUPLAZID (pimavanserin), for w...more

Web References(140 Total References)


ACADIA Pharmaceuticals Reports Third Quarter 2013 Financial Results » Pull 4 Parkinson's Foundation, Inc.

pull4parkinsonsfoundation.org [cached]

Thomas H. Aasen, Executive Vice President,
Chief Financial Officer and Chief Business Officer


SEC Filings - Investors - Acadia

ir.acadia-pharm.com [cached]

THOMAS H. AASEN.
We entered into an employment letter agreement with Thomas H. Aasen, dated March 4, 1998, providing for an initial annual salary of $160,000, subject to adjustment from time to time, plus bonuses based upon Mr. Aasen's individual performance and our financial performance as determined by our board of directors, a signing bonus of $20,000 and an opportunity to acquire 75,000 shares of common stock under our 1997 stock option plan. Under the terms of the agreement, Mr. Aasen's stock options will become fully vested upon a change of control of our company. If we terminate Mr. Aasen's employment for reasons other than cause, we are obligated to pay Mr. Aasen a severance of the continuation of his salary and other benefits he may be receiving at the time of termination for the one year period following his termination.


SEC Filings - Investors - Acadia

ir.acadia-pharm.com [cached]

THOMAS H. AASEN has served as our Vice President, Chief Financial Officer,
Secretary and Treasurer since April 1998. From June 1996 to April 1998, Mr. Aasen held the position of Senior Director of Finance and Administration at Axys Pharmaceuticals, formerly called Sequana Therapeutics, Inc. From October 1991 to June 1996, he served as Director of Finance at Genta, Inc., a 50


BioPharma News » BioPharma Stock Watch

biopharmadirectory.com [cached]

Thomas H. Aasen, CPA
Executive Vice President, Chief Financial Officer, and Chief Business Officer Mr. Aasen has been with ACADIA since April 1998. Prior to joining the company, Mr. Aasen held the position of Senior Director of Finance and Administration at Axys Pharmaceuticals, a publicly-traded, life-sciences company formerly called Sequana Therapeutics, where he was employed from June 1996 to April 1998. Earlier in his career, Mr. Aasen held various financial-management positions including Director of Finance at Genta, Inc., and Director of Accounting at Gen-Probe, Inc., both publicly-traded life-sciences companies as well as Audit Manager at KPMG Peat Marwick. He has over 23 years of professional finance and accounting experience focused primarily on the life-sciences industry. Mr. Aasen received a B.S. degree with honors from San Diego State University, and he is a Certified Public Accountant.


Acadia Pharmaceuticals - About Us - Management Team

www.acadia-pharm.com [cached]

Thomas H. Aasen
Thomas H. Aasen is our Executive Vice President, Chief Financial Officer, and Chief Business Officer and has been at ACADIA since April 1998. Prior to joining us, Mr. Aasen held financial management positions at several publicly traded life sciences companies, including Axys Pharmaceuticals, formerly called Sequana Therapeutics, Genta, Inc., and Gen-Probe, Inc. Earlier in his career, Mr. Aasen held various positions in public accounting at KPMG Peat Marwick, including Audit Manager. He has 30 years of professional finance and accounting experience focused primarily on the life sciences industry. Mr. Aasen received a B.S. degree with honors from San Diego State University and is a licensed certified public accountant (inactive status) in the State of California.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory